# reload+after+2024-01-21 09:46:45.981433
address1§1330 O’Brien Drive
city§Menlo Park
state§CA
zip§94025
country§United States
phone§650 752 1300
fax§650 752 1301
website§https://www.personalis.com
industry§Diagnostics & Research
sector§Healthcare
longBusinessSummary§Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test to optimize therapy selection and match patients to clinical trials; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications, such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves pharmaceutical, biopharmaceutical, diagnostic testing, and biotechnology companies; healthcare providers; universities; non-profits; and government entities. The company was incorporated in 2011 and is headquartered in Fremont, California.
fullTimeEmployees§395
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Christopher M. Hall', 'age': 54, 'title': 'President, CEO & Director', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 506392, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Aaron L. Tachibana', 'age': 62, 'title': 'CFO & COO', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 569602, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Richard  Chen M.D., M.S.', 'age': 52, 'title': 'Executive VP of R&D and Chief Medical Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 584168, 'exercisedValue': 0, 'unexercisedValue': 6262}, {'maxAge': 1, 'name': 'Dr. Russ B. Altman M.D., Ph.D.', 'title': 'Co-Founder and Member of Clinical & Scientific Advisory Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Euan A. Ashley DPHIL, FRCP, M.D., Ph.D.', 'age': 51, 'title': 'Co-Founder and Member of Clinical & Scientific Advisory Board', 'yearBorn': 1972, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Michael P. Snyder Ph.D.', 'title': 'Co-Founder and Member of Clinical & Scientific Advisory Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Stephen M. Moore J.D.', 'age': 50, 'title': 'VP, General Counsel & Corporate Secretary', 'yearBorn': 1973, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael J Fitzpatrick', 'title': 'Vice President of Worldwide Sales', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Christian  Haudenschild Ph.D.', 'title': 'Senior Vice President of Genomic Laboratory Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Stephane  Mouradian Ph.D.', 'title': 'Senior Vice President of Business Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§5
boardRisk§5
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.939
priceToSalesTrailing12Months§1.4877383
currency§USD
dateShortInterest§1702598400
forwardEps§-1.72
pegRatio§0.07
exchange§NGM
quoteType§EQUITY
shortName§Personalis, Inc.
longName§Personalis, Inc.
firstTradeDateEpochUtc§1561037400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f81834ed-ba4e-3518-a347-74e71fee4b87
gmtOffSetMilliseconds§-18000000
targetHighPrice§7.5
targetLowPrice§2.3
targetMeanPrice§4.7
targetMedianPrice§4.5
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§4.136
grossMargins§0.21715
ebitdaMargins§-1.34843
trailingPegRatio§None
